Between the pandemic and the rise of the Black Lives Matter movement in the US, biopharma companies have made it a priority in the past few years to improve diversity and inclusion. After talking to several companies shortlisted for their diversity and inclusion efforts in clinical research for the Citeline Awards, In Vivo identified some common themes that can help other companies looking to improve their own D&I work.
The biggest challenges included building trust and finding ways to reach the communities being targeted
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?